Flutemetamol (18F): Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A radiopharmaceutical used in PET imaging of the brain}} | |||
[[File:Flutemetamol_(18F).svg|thumb|right|Chemical structure of Flutemetamol (18F)]] | |||
Flutemetamol (18F) | |||
'''Flutemetamol (18F)''' is a [[radiopharmaceutical]] used in [[positron emission tomography]] (PET) imaging to visualize [[beta-amyloid]] plaques in the [[brain]]. These plaques are associated with [[Alzheimer's disease]] and other [[neurodegenerative disorders]]. | |||
Flutemetamol (18F) is used in PET imaging to | |||
== | ==Chemical composition== | ||
Flutemetamol (18F) | Flutemetamol (18F) is a [[fluorine-18]] labeled [[stilbene]] derivative. The [[fluorine-18]] isotope is a [[radioactive]] [[fluorine]] atom that emits [[positrons]], which are detected by PET scanners to create detailed images of the brain. | ||
== | ==Mechanism of action== | ||
Flutemetamol (18F) binds to [[beta-amyloid]] plaques in the brain. When administered to a patient, it crosses the [[blood-brain barrier]] and attaches to these plaques. The [[radioactive decay]] of fluorine-18 emits positrons, which interact with electrons in the brain tissue, producing [[gamma rays]] that are detected by the PET scanner. This allows for the visualization of amyloid plaque distribution and density. | |||
==Clinical use== | |||
Flutemetamol (18F) is primarily used in the diagnosis of [[Alzheimer's disease]]. It helps in the assessment of patients with cognitive impairment by providing images that show the presence or absence of amyloid plaques. This information can aid in distinguishing Alzheimer's disease from other types of [[dementia]]. | |||
==Safety and precautions== | |||
As with any radiopharmaceutical, there are safety considerations when using Flutemetamol (18F). The radiation dose is relatively low, but it is important to minimize exposure to both the patient and healthcare providers. Proper protocols should be followed to ensure safe handling and administration. | |||
==Related pages== | |||
* [[Alzheimer's disease]] | * [[Alzheimer's disease]] | ||
* [[Positron emission tomography]] | * [[Positron emission tomography]] | ||
* [[Radiopharmaceutical]] | * [[Radiopharmaceutical]] | ||
* [[ | * [[Beta-amyloid]] | ||
[[Category:Radiopharmaceuticals]] | [[Category:Radiopharmaceuticals]] | ||
[[Category:Medical imaging]] | |||
[[Category:Alzheimer's disease]] | [[Category:Alzheimer's disease]] | ||
Latest revision as of 11:38, 15 February 2025
A radiopharmaceutical used in PET imaging of the brain
.svg)
Flutemetamol (18F) is a radiopharmaceutical used in positron emission tomography (PET) imaging to visualize beta-amyloid plaques in the brain. These plaques are associated with Alzheimer's disease and other neurodegenerative disorders.
Chemical composition[edit]
Flutemetamol (18F) is a fluorine-18 labeled stilbene derivative. The fluorine-18 isotope is a radioactive fluorine atom that emits positrons, which are detected by PET scanners to create detailed images of the brain.
Mechanism of action[edit]
Flutemetamol (18F) binds to beta-amyloid plaques in the brain. When administered to a patient, it crosses the blood-brain barrier and attaches to these plaques. The radioactive decay of fluorine-18 emits positrons, which interact with electrons in the brain tissue, producing gamma rays that are detected by the PET scanner. This allows for the visualization of amyloid plaque distribution and density.
Clinical use[edit]
Flutemetamol (18F) is primarily used in the diagnosis of Alzheimer's disease. It helps in the assessment of patients with cognitive impairment by providing images that show the presence or absence of amyloid plaques. This information can aid in distinguishing Alzheimer's disease from other types of dementia.
Safety and precautions[edit]
As with any radiopharmaceutical, there are safety considerations when using Flutemetamol (18F). The radiation dose is relatively low, but it is important to minimize exposure to both the patient and healthcare providers. Proper protocols should be followed to ensure safe handling and administration.
